Search the Newsroom
Filter By
News Type
Showing 1 - 10 of 38 results
Planting the Seeds of a Healthy Diet
The innovative Food as Medicine program bring food and nutrition education to families facing food instability.
New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Volunteer Spotlight: Dianne Motil
Dianne Motil started her CHOP career four years ago as a registered nurse in Primary Care, and throughout the years has transferred and now works in the PICU/Onco Unit at Middleman Family Pavilion in King of Prussia.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
Volunteer Spotlight: Rachel Walega
Eighteen months ago, the Office of Endocrinology and Diabetes welcomed Rachel Walega to their team as a Clinical Research Project Manager. There, Rachel works on projects in Cystic Fibrosis related diabetes, Down syndrome and bone fragility.
CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.